Alchemab Therapeutics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

alchemab.com

Founded Year

2019

Stage

Series A | Alive

Total Raised

$82M

Last Raised

$82M | 1 yr ago

About Alchemab Therapeutics

Alchemab Therapeutics uses patient antibodies to keep them free of hard-to-treat diseases.

Alchemab Therapeutics Headquarter Location

55-56 Russell Square

Bloomsbury, England, WC1B 4HP,

United Kingdom

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Alchemab Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Alchemab Therapeutics is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest Alchemab Therapeutics News

Time Partners closes £30M venture fund to back life sciences startups

Jun 28, 2022

Photo/Shutterstock Time Partners Limited has announced the final closing of its first advised fund, Time Boost Capital I LP, a £30 million ($36.6 million) genomics venture fund to provide match funding to startups graduating from Illumina Accelerator Cambridge, UK. Since opening in July 2020, Illumina Accelerator Cambridge has launched 13 startups focused on harnessing genomics applications to improve human health, including novel therapeutics, diagnostics, synthetic biology, research tools, and agriculture. Time Boost Capital’s commitments comes from a group of global investors, including LifeArc, a UK independent medical research charity; Illumina Inc, the listed parent of Illumina Accelerator Cambridge; and Illumina Ventures, an independent fund investing in genomics and precision health. Time Boost Capital will provide pound-for-pound match funding to every Illumina Accelerator Cambridge graduate that secures between £500,000 up to £4 million ($610,000 to $4.9 million) in new capital from qualified investors, within 18 months of acceptance. Illumina Accelerator Cambridge alumni includes Alchemab Therapeutics LTD, a therapeutics company pioneering the next generation of antibody drugs that went on to raise £60 million ($73 million) in Series A funding upon graduation. A recent graduate is Broken String Biosciences Limited, a sequencing tools company focused on assessing the stability of the genome that secured £3 million ($3.7 million) in seed funding including funding from Time Boost Capital. Content continues below Related Content “At Time Partners, we are proud to partner with Illumina, a global leader in next generation sequencing technologies. Illumina is making a significant commitment to supporting new growth in the field through Illumina Accelerator,” said Mark Florman, CEO of Time Partners Limited. “As an investment adviser to Time Boost Capital, we have the unique opportunity to back some of the most promising new genomics businesses.” Explore Related Topics:

Alchemab Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Alchemab Therapeutics Rank

  • When was Alchemab Therapeutics founded?

    Alchemab Therapeutics was founded in 2019.

  • Where is Alchemab Therapeutics's headquarters?

    Alchemab Therapeutics's headquarters is located at 55-56 Russell Square, Bloomsbury.

  • What is Alchemab Therapeutics's latest funding round?

    Alchemab Therapeutics's latest funding round is Series A.

  • How much did Alchemab Therapeutics raise?

    Alchemab Therapeutics raised a total of $82M.

  • Who are the investors of Alchemab Therapeutics?

    Investors of Alchemab Therapeutics include DHVC, SV Health Investors, RA Capital Management, Data Collective, Lightstone Ventures and 4 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.